BridgeBio Pharma BBIO Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Segments
By product
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's other non-current liabilities?
- BridgeBio Pharma (BBIO) reported other non-current liabilities of $229K in Q1 2026.
- How has BridgeBio Pharma's other non-current liabilities changed year-over-year?
- BridgeBio Pharma's other non-current liabilities decreased by 34.9% year-over-year, from $352K to $229K.
- What is the long-term trend for BridgeBio Pharma's other non-current liabilities?
- Over 5 years (2020 to 2025), BridgeBio Pharma's other non-current liabilities has grown at a -51.9% compound annual growth rate (CAGR), from $9.52M to $244K.
- What does other non-current liabilities mean?
- Miscellaneous long-term debts and obligations not classified elsewhere on the balance sheet.
- How do you interpret other non-current liabilities?
- An unexpected increase may signal rising long-term operational risks or changes in accounting estimates for contingent liabilities.
- How does other non-current liabilities compare across companies?
- Varies widely based on company-specific accounting policies and acquisition history.